Immix Biopharma Inc. (IMMX)
NASDAQ (CM) NASDAQ (CM) Primary 
Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition
Immix Biopharma (IMMX) is advancing NXC-201, a one-time CAR T therapy for AL amyloidosis, showing 95% complete/near-complete response rates and superior safety. IMMX's recent $100 million financing removes capital overhang, strengthens negotiating position, and supports a clear path toward BLA submission in mid-2026. With reasonable peak revenue scenarios ranging from $320 million to over $1 billion annually, the current sub-$400 million valuation presents further upside.
Immix Biopharma: I Am Surprised To Reaffirm A 'Buy'
Immix Biopharma has provided only faint early signals of its flagship CAR T-cell therapy in AL amyloidosis. However, an upcoming data presentation at ASH should shed more light on the prospects of a potential FDA submission in 2026. Cash remains an issue, although IMMX has secured funding through a strategic investment to get them through the next few quarters.
Immix Biopharma (IMMX) Upgraded to Buy: What Does It Mean for the Stock?
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
What Makes Immix Biopharma (IMMX) a New Buy Stock
Immix Biopharma (IMMX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
